Drug Trial Radar · NCT07940439
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Dec 2030
Study completion Jun 2031
Sponsor
- Lead sponsor
- Chengdu Suncadia Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety and tolerability of HRS-9308 tablet in participants with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended dose for Phase II clinical studies (RP2D) of HRS-9308.
Conditions
- Solid Tumor
Interventions
HRS-9308 TabletDrug
HRS-9308 tablet, with different doses, in Stage I, Stage II or Stage III.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events (AEs)Time frame: From Day 1 to 40 days after the last dose.
- Dose-limiting toxicity (DLT)Time frame: From Day 1 to 12 months.
- Maximum tolerated dose (MTD)Time frame: From Day 1 to 12 months.
- Recommended dose for Phase II clinical studies (RP2D)Time frame: From Day 1 to 12 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.